179 related articles for article (PubMed ID: 23506208)
1. Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach.
Bartels C; Looby M; Sechaud R; Kaiser G
Br J Clin Pharmacol; 2013 Dec; 76(6):868-79. PubMed ID: 23506208
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects.
Sechaud R; Machineni S; Tillmann HC; Hara H; Tan X; Zhao R; Ren S; Hou J
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):723-731. PubMed ID: 26428357
[TBL] [Abstract][Full Text] [Related]
3. Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease.
Carter NJ
Drugs; 2013 May; 73(7):741-53. PubMed ID: 23677802
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD).
Sechaud R; Renard D; Zhang-Auberson L; Motte Sde L; Drollmann A; Kaiser G
Int J Clin Pharmacol Ther; 2012 Feb; 50(2):118-28. PubMed ID: 22257577
[TBL] [Abstract][Full Text] [Related]
5. Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.
Molimard M; D'Andrea P
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):503-17. PubMed ID: 23971870
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
[TBL] [Abstract][Full Text] [Related]
7. Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).
Ulrik CS
Expert Opin Pharmacother; 2015; 16(17):2653-9. PubMed ID: 26641535
[TBL] [Abstract][Full Text] [Related]
8. A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
Arievich H; Overend T; Renard D; Gibbs M; Alagappan V; Looby M; Banerji D
BMC Pulm Med; 2012 Dec; 12():74. PubMed ID: 23217058
[TBL] [Abstract][Full Text] [Related]
9. Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit.
Ulrik CS
Int J Chron Obstruct Pulmon Dis; 2012; 7():673-8. PubMed ID: 23055716
[TBL] [Abstract][Full Text] [Related]
10. Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
Riario-Sforza GG; Ridolo E; Riario-Sforza E; Incorvaia C
Expert Rev Respir Med; 2015 Feb; 9(1):23-33. PubMed ID: 25547422
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects
.
Ren S; Sechaud R; Su Z; Tillmann HC; Hara H; Tan X; Hou J; Woessner R; Zhao R
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):147-155. PubMed ID: 27841152
[TBL] [Abstract][Full Text] [Related]
12. Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Prakash A; Babu KS; Morjaria JB
Int J Chron Obstruct Pulmon Dis; 2015; 10():111-23. PubMed ID: 25609944
[TBL] [Abstract][Full Text] [Related]
13. Relative Bioavailability of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Administered With and Without a Spacer: Results of a Phase I, Randomized, Crossover Trial in Healthy Adults.
Dorinsky P; DePetrillo P; DeAngelis K; Trivedi R; Darken P; Gillen M
Clin Ther; 2020 Apr; 42(4):634-648. PubMed ID: 32253054
[TBL] [Abstract][Full Text] [Related]
14. [New therapeutic choice for COPD: glycopyrronium bromide, a long-acting muscarinic antagonist].
Yoshisue H; Kozawa M; Hiratsuka M; Nakanishi M
Nihon Yakurigaku Zasshi; 2013 Oct; 142(4):190-9. PubMed ID: 24107524
[No Abstract] [Full Text] [Related]
15. Glycopyrronium does not affect QT interval in healthy subjects: a randomized, three- period, cross-over, placebo- and positive-controlled study.
Drollmann A; Sechaud R; Pal P; Hara H; Uziel-Fusi S; Winkle P
Int J Clin Pharmacol Ther; 2014 Sep; 52(9):739-45. PubMed ID: 24986094
[TBL] [Abstract][Full Text] [Related]
16. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
Ulrik CS
Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Dahl R; Jadayel D; Alagappan VK; Chen H; Banerji D
Int J Chron Obstruct Pulmon Dis; 2013; 8():501-8. PubMed ID: 24159259
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.
Dunn LJ; Kerwin EM; DeAngelis K; Darken P; Gillen M; Dorinsky P
Pulm Pharmacol Ther; 2020 Feb; 60():101873. PubMed ID: 31841699
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
Demin I; Bartels C; Graham G; Bieth B; Gautier A; Tillmann HC; Sechaud R
Int J Clin Pharmacol Ther; 2016 Jun; 54(6):405-15. PubMed ID: 27049057
[TBL] [Abstract][Full Text] [Related]
20. The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults.
Darken P; DePetrillo P; Reisner C; St Rose E; Dorinsky P
Pulm Pharmacol Ther; 2018 Jun; 50():11-18. PubMed ID: 29544728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
